The Compound · News
CagriSema REDEFINE 9 results: about 21% weight loss at lower doses
REDEFINE 9 found that CagriSema at 1.0 mg/1.0 mg and 1.7 mg/1.7 mg cut body weight by about 21% over 68 weeks, against 2% on placebo. Novo Nordisk presented the full data at ObesityWeek 2026 on November 14. The headline is not the number. It is that a lower dose got most of the way to what the full dose did.
What did REDEFINE 9 find?
REDEFINE 9 is the first Phase 3 weight-loss trial of CagriSema below the 2.4 mg/2.4 mg dose. Novo Nordisk randomized 309 adults with obesity, or overweight plus at least one weight-related condition, and no diabetes. People got CagriSema 1.0 mg/1.0 mg (103 people), CagriSema 1.7 mg/1.7 mg (104 people), or a matching placebo (102 pooled). Average starting weight was 109.5 kg, about 241 pounds. Everyone got diet and exercise counseling. At 68 weeks, both doses beat placebo by a wide margin. The results were presented at ObesityWeek 2026 in Washington, DC on November 14 and published the same day in The Lancet Diabetes & Endocrinology. Novo had released a one-line topline in September. This is the first full look.
CagriSema REDEFINE 9 results by dose
Trials like this report two numbers. The first assumes everyone took the drug as planned. The second counts everyone who was randomized, including people who quit or needed rescue treatment. The second is closer to what happens in real life. Both are in the table, all at week 68.
| Outcome (week 68) | 1.0 mg/1.0 mg | 1.7 mg/1.7 mg | Placebo |
|---|---|---|---|
| Weight loss, stayed on treatment | 21.0% | 20.7% | 2.0% |
| Weight loss, everyone randomized | 18.6% | 19.4% | 4.6% |
| Lost 10% or more (on treatment) | 86.0% | 87.3% | 13.6% |
| Lost 15% or more (on treatment) | 70.7% | 70.5% | 5.8% |
| Lost 20% or more (on treatment) | 48.3% | 51.3% | 2.7% |
| Quit due to side effects | 4.9% | 2.9% | 4.9% |
The two doses are basically tied. The lower dose edges ahead on one estimate and behind on the other, and Novo says plainly that the trial was not powered to tell them apart. Treat them as the same result.
Is lower-dose CagriSema as effective as the full 2.4 mg dose?
This is the question people will actually search, and the honest answer is that REDEFINE 9 points that way without proving it. The full 2.4 mg/2.4 mg dose produced 22.7% mean weight loss at 68 weeks in REDEFINE 1, a much larger trial of 3,417 adults. REDEFINE 9 got about 21% with less than half the drug. But these are different trials with different people, and REDEFINE 9 never included a 2.4 mg arm. A gap of under two points across two separate studies is within the range that trial-to-trial differences can produce on their own.
What the data does support: the dose-response curve for CagriSema looks flat at the top. If it holds up, it matters for tolerability, for supply, and eventually for price.
Why a lower dose matters for side effects and cost
The GLP-1 drugs on the market are mostly dosed by titrating up until side effects or weight loss stall. Nausea is the usual ceiling. A drug that gets near its maximum effect at a middle dose gives prescribers room to stop climbing, and gives patients a reason not to push through a rough few weeks. REDEFINE 9 does not show fewer side effects at the lower dose. The 1.0 mg arm actually had slightly more people quit. But it gives a doctor evidence that stopping at a lower step is not leaving much weight loss on the table.
Cost is the other angle. Less drug per shot means more doses per batch of manufacturing capacity. Novo has not said anything about price or about filing the lower doses. For what the drugs you can actually get today cost per month, see our GLP-1 cost comparison and the breakdown of what semaglutide costs online.
How does CagriSema compare with tirzepatide now?
The comparison that still hangs over CagriSema is REDEFINE 4. In that trial, full-dose CagriSema produced 23% weight loss versus 25.5% for tirzepatide 15 mg, and it missed its non-inferiority goal. REDEFINE 9 does not change that. It is a placebo trial. In September 2026, Novo also announced REIMAGINE 5, where CagriSema 1.0 mg/1.0 mg beat tirzepatide 5 mg on weight loss in type 2 diabetes, 12.4% to 9.1%. That is a real result, but 5 mg is tirzepatide's starting dose, not where most people end up. Our semaglutide vs tirzepatide page covers the two drugs you can actually be prescribed today.
When will CagriSema be available?
Current status, November 15, 2026
- FDA application for CagriSema 2.4 mg/2.4 mg filed December 2025
- Novo Nordisk expects an FDA decision in Q4 2026. None announced yet
- The 1.0 mg and 1.7 mg doses from REDEFINE 9 are not part of the current filing
- Not approved, not available by prescription, no legitimate compounded version
If the FDA approves the pending application, the first CagriSema on the market will be the 2.4 mg/2.4 mg dose. REDEFINE 9 gives Novo the evidence to add lower maintenance doses later, either through a label update or a separate filing. Until then, semaglutide and tirzepatide are the approved options. Anyone selling "CagriSema" online today is selling something that has not been through FDA review.
Frequently Asked Questions
Sources
- Novo Nordisk: CagriSema demonstrated ~21% average weight loss with lower doses in REDEFINE 9, presented at ObesityWeek 2026 and published in The Lancet Diabetes & Endocrinology (November 14, 2026)
- BioPharm International: Novo Nordisk CagriSema beats tirzepatide for weight loss in Phase 3 trial, REIMAGINE 5 and REDEFINE 9 topline (September 22, 2026)
- Health Research Authority: REDEFINE 9 study summary, different doses of CagriSema in people with excess body weight
- Garvey et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1), N Engl J Med 2025
- Novo Nordisk files for FDA approval of CagriSema for weight management (December 2025)
- HCPLive: CagriSema demonstrates weight loss, fails primary endpoint compared to tirzepatide (REDEFINE 4)
